Abstract
Background
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder typified by various combination of numerous Café-au-lait macules, cutaneous and plexiform neurofibromas, freckling of inguinal or axillary region, optic glioma, Lisch nodules and osseous lesions. Cherubism is a rare genetic syndrome described by progressive swelling of the lower and/or upper jaw due to replacement of bone by fibrous connective tissue. Patients are reported in the literature with NF1 and cherubism-like phenotype due to the NF1 osseous lesions in the jaws. The purpose of this case report is the description of a young male genetically diagnosed with both NF1 and cherubism.
Methods and results
A 9 years and six month old patient with clinical findings of NF1 and cherubism in whom both diseases were genetically confirmed, is presented. The patient was evaluated by a pediatrician, a pediatric endocrinologist, an ophthalmologist, and an oral and maxillofacial surgeon. A laboratory and hormonal screening, a histological examination, a chest X-ray, a magnetic resonance imaging (MRI) of the orbit and a digital panoramic radiography were performed. Genetic testing applying Whole Exome Sequencing was conducted.
Conclusions
A novel and an already reported pathogenic variants were detected in NF1 and SH3BP2 genes, respectively. This is the first described patient with coexistence of NF1 and cherubism. The contribution of Next Generation Sequencing (NGS) in gene variant identification as well as the importance of close collaboration between laboratory scientists and clinicians, is highlighted. Both are essential for optimizing the diagnostic approach of patients with a complex phenotype.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Neurofibromatosis type 1 (NF1) is a clinically diverse, neurocutaneous hereditary syndrome that affects approximately 1:2600 to 1:3000 individuals [1]. NF1 is caused by mutations in the tumor suppressor neurofibromin 1 -NF1- gene [2], which codes for a protein that regulates the RAS signalling pathway [3]. Clinical features of NF1 are highly variable and include multiple café-au-lait macules (CALMs), Lisch nodules in the iris of the eyes, neurofibromas in the skin, plexiform neurofibromas (PNFs), and osseous defects. On the other hand, Cherubism is an uncommon inherited syndrome characterized by progressive bilateral enlargement of the mandible and/or maxilla and it is caused by mutations in the SH3PB2 gene (4p16.3) [4].
Cherubism’s characteristic facial phenotype is often clinically indistinguishable from NF1, because both are associated with osseous tissue malformations. Although, there are patients reported with NF1 and cherubism-like phenotype, there is no literature report with a genetically proven co-existence of both genetic diseases [5,6,7]. According to our knowledge, this case report describes the first pediatric patient with mutations in both NF1 and SH3PB2 genes and clinical manifestations of both diseases.
Case presentation
A 9 years and six month old male presented to our medical center with his family for consultation regarding facial dysmorphism. Medical history records were significant of dysplasia of the upper and lower jaw which started at the age of 5 years of age with a slow gradual progression over time. A NF1 clinical phenotype was reported in his father with mild clinical features, but, unfortunately, genetic testing cannot be conducted, as he was killed in a car accident. No other relevant family history of jawbone or maxilla enlargement was reported (Fig. 1). Clinical examination of our patient revealed NF1-related manifestations, including multiple CALMs (eleven with a diameter > 5 mm) and thoracic and lumbar spine scoliosis. Lisch nodules and cutaneous/dermal neurofibromas (CNFs) were absent. The examination was also significant for full round cheeks and upward cast of the eyes, possibly due to the progressive painless bilateral enlargement of both the lower and the upper jaws, creating the characteristic “cherubic” appearance. Moreover, abnormal dentition with alteration in teeth shape, displaced roots and increased tooth mobility and instability were identified. Annual growth rate of the patient was borderline since infancy, growing along the 3rd percentile for height and having a height of 125.8 cm at 96/12 years. His weight was 30 kg and his body mass index (BMI) 18,5 kg/m2 (85th percentile) and he reported a low weight gain rate over the last few years. Laboratory tests for follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, DHEA sulfate (DHEAS), 17-0 H progesterone, adrenocorticotropic hormone (ACTH), cortisol, prolactin, thyroid stimulating hormone (TSH), free thyroxine (fT4), insulin-like growth factor-1 (IGF-1), parathyroid hormone (PTH), 25-hydroxy vitamin D (25(OH)D), 1,25-dihydroxy vitamin D (1.25(OH)2D), calcium, and phosphate, tissue transglutaminase IgA antibody (tTG IgA) for celiac disease and ferritin, were performed with no abnormal results.
Computer tomography (CT) of the visceral cranium and Magnetic resonance imaging (MRI) of the orbit and the brain revealed osteolytic lesions with increased dimensions of intraosseous formations in the maxilla, mandible, and both zygomatic bones. Diffusion weighted imaging (DWI) showed no diffusion inside the osteolytic lesions, supporting the diagnosis of benign malformations. Additionally, MRI showed multiple hamartomatous lesions on both the left and the right cerebellar peduncles, the posterior aspect of the putamen, both the hypothalami, and the left thalamus. Furthermore, a cisterna magna malformation of the posterior fossa and bilateral cervical reactive lymphadenopathy were noticed.
A histological examination of the maxillary and mandibular lesions was carried out. Two white-yellow (max diameter 0.9 cm, 0.7 cm) fragments and, two red-gray pieces of tissue of soft consistency were received (m.d. 0.5 cm, 0.7 cm). The biopsy identified a central giant cell granuloma. Histologic features included multinucleated giant cells of osteoclastic type, which were scattered within richly vascularized myofibroblastic and fibrous connective tissue with hemorrhagic spots. The myofibroblastic stromal element consisted of bundles of interlaced ovoid or spindle-shaped mononuclear cells, fusion of which resulted in formation of syncytia with multinucleated osteoclastic cells. Furthermore, proteinaceous eosinophilic depositions were distributed throughout the perivascular space. Lastly, immunohistochemical analysis was conducted. Calponin, smooth muscle actin (SMA), CD68 KP1, CD163 and leukocyte common antigen (LCA) were expressed. In conclusion, the above-mentioned findings support the diagnosis of cherubism.
NF1 diagnosis
The possible diagnosis of NF1 in our patient was examined on the basis of the most recently updated (2021) diagnostic criteria for NF1 [8]. The only positive criterion for our patient was the presence of 11 CALMs with a diameter > 5 mm. His father had a similar clinical appearance suggestive of NF1, namely multiple CALMs, but he had not been genetically tested. Therefore, according to the relevant criteria, the clinical diagnosis of NF1 in the proband could not be established. Nevertheless, our clinical assumption of NF1 was strong enough to proceed with a genetic test, which confirmed our hypothesis.
Cherubism diagnosis
Cherubism diagnosis is clinically established based on age, family history, typical clinical, radiographic, and histologic findings. This 9 years and six month old male with no relevant family history of cherubism appeared with bilateral dysplasia of maxilla and mandible which corresponded to osteolytic lesions on CT and MRI, central giant cell granuloma on histological examination and positively expressed specific immunohistochemical agents.
Differential diagnosis
More than 100 genetic conditions that include CALMs or other NF1 features have been described. In Table 1, the most relevant conditions, and associated genes of interest in the differential diagnosis of NF1 are summarized [3].
Genetic testing
Ethical approval for the genetic study was acquired from St. Sophia Children’s Hospital Scientific and Ethics Committee (Approval number: 3669/12-02-18). All patient data were processed and stored according to the guidelines of the General Data Protection Regulation (GDPR). Written informed consent was provided by the patient’s parents. Following pre-test counselling proband only-WES (~ 20,000 genes) was performed, using genomic DNA extracted from whole blood. Library preparation was implemented using IDT xGen Exome Research v2 kit (Integrated DNA Technologies). The resulting libraries were subjected to paired-end sequencing on an Illumina NextSeq 500 platform. WES data from the bioinformatic analysis contained 102.138.898 number of reads and 25.169 variants (Fig. 2). The percentage of regions with at least 20X coverage was 98,5% and the mean coverage was 151X. Variant analysis was performed using VarSome Clinical platform [9] and was based on the phenotype-driven strategy [10]. For the variant classification, American College of Medical Genetics and Genomics (ACMG) guidelines were used [11]. Targeted Sanger sequencing for the specific variants in NF1 and SH3BP2 genes was performed for confirmation (Fig. 3).
Applying filter criteria based on phenotype-driven strategy [acceptance quality metrics, correlated phenotype using Human Phenotype Ontology terms (https://hpo.jax.org/app/), population frequency (GnomAD database, https://gnomad.broadinstitute.org), variant type, in-silico tools prediction, inheritance and allele state, variant classification), two heterozygous variants in different genes were detected. A novel nonsense variant NM_000267.3:c.2205T > A, p.(Tyr735*) in the NF1 gene was detected, which is classified as pathogenic (PVS1, PM2, PP4) and an already reported missense variant NM_003023.4:c.1253 C > T, p.(Pro418Leu) in the SH3BP2, which is classified also as pathogenic (PM1, PM2, PM5, PP3, PP5) [12]. Unfortunately, family members for further genetic investigation were not available. In summary, the simultaneous occurrence of neurofibromatosis and cherubim were indisputably demonstrated.
Discussion
To the best of our knowledge, this is the first report of the genetically verified coexistence of cherubism and NF1 in a pediatric patient. It underlines the important role of the genetic testing using NGS techniques and of the close collaboration between laboratory scientists and clinicians. ΝF1 diagnosis was clinically considered for our patient due to family history, but the imaging and histological findings revealed the co-existence of two different disorders.
Many nosological entities are characterized by mandibular and maxillary lesions. Cherubic habitus may be present in RASopathy syndromes, giant cell lesions of the jaws (GCLJ), hyperparathyroidism-jaw tumor (HPT-JT) syndrome, fibrous dysplasia/ McCune-Albright syndrome (FD/MAS), familial isolated hyperparathyroidism (OMIM 145,000), and Ramon syndrome (OMIM 266,270) [4] (Table 1).
NF1 belongs to the family of RASopathy disorders, arising from common genetic modifications in genes of the Ras/mitogen-activated protein kinase (MAPK) pathway [2, 13, 14]. Besides NF1, this group includes neurofibromatosis type 1–like syndrome (NFLS or Legius syndrome), Noonan syndrome (NS), Noonan syndrome with multiple lentigines (NSML or LEOPARD syndrome), Costello syndrome (CS), Cardio-Facio-Cutaneous (CFC) syndrome and Capillary Malformation–Arteriovenous Malformation syndrome (CM-AVM). Each of these possesses unique clinical features but many are common among the different syndromes such as, craniofacial dysmorphology, cardiovascular deformities, skeletal abnormalities, cutaneous lesions, neurocognitive impairment, and increased tumor risk. RASopathy syndromes may rarely appear simultaneously with Giant cell lesions of the jaws (GCLJ) which comprise an assembly of ailments depicted by deformities in the mandible and maxilla, concretely by multinucleated giant cells on histopathology examination [14]. Cherubism, Central giant cell granuloma, Brown tumor of hyperparathyroidism and Aneurysmal bone cyst are the main components of the GCLJ group [15].
NF1 is inherited in an autosomal dominant manner and is caused by loss-of-function variants in the NF1 tumor suppression gene situated on 17q11.2. It is mainly branded by cutaneous neurofibromas, CALMS, optic gliomas, Lisch nodules and bone lesions. Osseous deformities including scoliosis, macrocephaly, and intraoral malformations can occur affecting soft tissues, dentition, mandible and maxilla [2]. Neurofibroma-induced facial abnormalities have not been reported in all patients and therefore, further investigation is necessary when NF1 patient presents with a facial abnormality. In this case report, the patient had bilateral enlargement of both the lower and the upper jaw and met the diagnostic criteria for NF1. Therefore, a CT scan and an MRI were preformed and revealed osteolytic lesions which were thought to be NF1 manifestations.
Regarding cherubic habitus, one of the main associated syndromes is Noonan syndrome (NS), a disorder of autosomal dominant inheritance. Characteristic findings include peculiar facial phenotype, short stature, a broad or webbed neck, congenital cardiac defects, coagulation complications, osseous deformities, and developmental impairment [6, 13,14,15,16]. Diagnosis of NS is established genetically by finding pathogenic variant in any of the following genes: PTPN11, SOS1, SOS2, RAF1, KRAS, NRAS, MRAS, MAP2K1, BRAF, RASA2, LZTR1, RRAS and RIT1. Noonan syndrome with multiple lentigines (NSML or LEOPARD syndrome), must also be included in the differential diagnosis. Cardinal features of NSML are lentigines, cardiac abnormalities (hypertrophic cardiomyopathy), diminutive stature, pectus excavatum and dysmorphic facies, comprising wide set eyes and ptosis [16]. Genetic testing is important since NSML is caused by mutations in BRAF, MAP2K1, PTPN11, and RAF1. Finally, a RASopathy syndrome, which should be considered in our case is Cardiofaciocutaneous (CFC) syndrome. CFC is characterized by dysmorphic craniofacial features, cardiac anomalies, neuromotor delay, cognitive impairment, ectodermal findings (xerosis cutis, sparse, curly and woolly or brittle hair, dystrophic nails), eye abnormalities (strabismus, nystagmus, and/or optic nerve hypoplasia) and hypotonia and is associated with alterations in BRAF, MAP2K1, MAP2K2, or KRAS genes [17]. As already mentioned, RASopathies share common clinical manifestations and overlapping mutated genes. NS, NSML and CFC were excluded from the possible diagnosis, as our patient tested negative for the corresponding genes.
The classic cherubic appearance is also a feature of Ramon syndrome. It is a rare autosomal recessive disorder characterized by gingival fibromatosis, bilateral painless swelling of the mandible and maxilla, epilepsy, intellectual disability, stunted growth, hypertrichosis, juvenile rheumatoid arthritis, and ocular abnormalities [18]. However, in our case, the absence of mental retardation, epilepsy, and gingival fibromatosis distinguishes cherubism from Ramon syndrome.
Hyperparathyroidism-jaw tumor syndrome (HPT-JT or HRPT2) and Familial isolated primary hyperparathyroidism (FIHP, HRPT1) are autosomal dominant disorders derived by a germline alteration of the cell division cycle 73 (CDC73) gene (1q31.2). This gene encodes for parafibromin which is a critical component of PAF1 complex that binds to RNA polymerase II and controls transcription [19]. Clinical manifestations of HPT-JT include highly elevated serum PTH levels, hypercalcemia, parathyroid adenomas and fibro-osseous tumors in the mandible and maxilla, kidneys and uterus. Jaw tumors are benign, bilateral or multifocal, enlarged, palpable or visible radiolucent mass lesions and fibro-osseous characterized by the presence of giant cells. FIHP is also characterized by increased levels of parathyroid hormone (PTH), calcium and alkaline phosphatase and is responsible for benign fibro-osseous giant cell lesions (brown tumors) in mandible and maxilla [20]. Both HPT-JT and FIHP can be distinguished from cherubism on the basis of increased levels of PTH, serum calcium, serum phosphorus and alkaline phosphatase. Our patient’s blood test results were within the normal range for the above-mentioned parameters and therefore both HPT-JT and FIHP were excluded from the differential diagnosis.
Another disease that should be included in the differential diagnosis is Fibrous dysplasia/McCune-Albright syndrome (FD/MAS). FD/MAS is a rare sporadically occurring syndrome derived by alteration in the GNAS gene (20q13.32) leading to excess production of cyclic AMP (cAMP) and therefore leading to proliferation and fibrosis of bone marrow stromal cells [21]. Clinically FD/MAS is characterized by polyostotic fibrous dysplasia (POFD), CALMS, and peripheral precocious puberty. On CT FD lesions have a characteristic ground-glass appearance, which are not observed radiographically in cherubism lesions [22]. In our case, FD/MAS was excluded based on the absence of this radiographic pattern and a negative genetic test for GNAS gene.
Central giant-cell granuloma (CGCG) is a rare non-odontogenic osteolytic disease that usually affects the jaw bones. The pathogenesis is unknown and CGCG is considered a benign asymptomatic swelling of the jaws, which histopathologically is characterized by multinucleated osteoclast-like giant cells, extravasated erythrocytes and a fibrous connective tissue stroma, which is similar to the histological profile of cherubism [5, 23]. Despite that, it has been reported that perivascular eosinophilic cufflike deposition is a specific histopathologic feature of cherubism [24]. In the present case, the patient not only had bilateral osteolytic lesions, but also had proteinaceous eosinophilic accumulation in the perivascular space effectively excluding CGCG from the differential diagnosis.
In conclusion, we report the co-occurrence of NF1 and SH3BP2 pathogenic variants in a case with NF1-related manifestations and cherubic phenotypic features. Since several nosological entities could share common clinical characteristics, genetic testing is a valuable tool in the pediatrician’s diagnostic armamentarium. Accurate diagnosis is of outmost importance, if we are to offer the best possible therapeutic guidance and reproductive options to these patients and/or their families.
Data availability
PubMed was used as a source of information and all additional data are available on request.
References
Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152(2):327 – 32. https://doi.org/10.1002/ajmg.a.33139. PMID: 20082463
Luna EB, Janini ME, Lima F, Pontes RR, Guedes FR, Geller M, da Silva LE, Motta AT, Cunha KS (2018) Craniomaxillofacial morphology alterations in children, adolescents and adults with neurofibromatosis 1: a cone beam computed tomography analysis of a Brazilian sample. Med Oral Patol Oral Cir Bucal 23(2):e168–e179. https://doi.org/10.4317/medoral.22155. PMID: 29476678; PMCID: PMC5911357
Friedman JM, Neurofibromatosis (1998) 1. Oct 2 [Updated 2022 Apr 21]. In: Adam MP, Feldman J, Mirzaa GM, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1109/
Kannu P, Baskin B, Bowdin SC (2007) Feb 26 [Updated 2018 Nov 21]. In: Adam MP, Feldman J, Mirzaa GM, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1137/
Friedrich RE, Zustin J, Luebke AM, Rosenbaum T, Gosau M, Hagel C, Kohlrusch FK, Wieland I, Zenker M Neurofibromatosis type 1 with cherubism-like phenotype, multiple osteolytic bone lesions of lower extremities, and Alagille-syndrome: Case Report with Literature Survey. In Vivo 2021 May-Jun 35(3):1711–1736. https://doi.org/10.21873/invivo.12431. PMID: 33910856; PMCID: PMC8193341.
van Capelle CI, Hogeman PH, van der Sijs-Bos CJ, Heggelman BG, Idowu B, Slootweg PJ, Wittkampf AR, Flanagan AM (2007) Neurofibromatosis presenting with a cherubism phenotype. Eur J Pediatr 166(9):905–909. https://doi.org/10.1007/s00431-006-0334-6Epub 2006 Nov 21. PMID: 17120035
Chrcanovic BR, Gomez RS, Freire-Maia B (2011) Neurofibromatosis type 1 associated with bilateral central giant cell granuloma of the mandible. J Craniomaxillofac Surg 39(7):538 – 43. https://doi.org/10.1016/j.jcms.2010.10.014. Epub 2010 Nov 11. PMID: 21071237
Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC), Huson SM, Evans DG, Plotkin SR (2021) Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 23(8):1506–1513. https://doi.org/10.1038/s41436-021-01170-5. Epub 2021 May 19. PMID: 34012067; PMCID: PMC8354850
Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Aguilera MA, Meyer R, Massouras A (2019) VarSome: the human genomic variant search engine. Bioinformatics 35(11):1978–1980. https://doi.org/10.1093/bioinformatics/bty897
Marinakis NM, Svingou M, Veltra D, Kekou K, Sofocleous C, Tilemis FN, Kosma K, Tsoutsou E, Fryssira H, Traeger-Synodinos J (2021) Phenotype-driven variant filtration strategy in exome sequencing toward a high diagnostic yield and identification of 85 novel variants in 400 patients with rare mendelian disorders. Am J Med Genet A 185(8):2561–2571. Epub 2021 May 19. PMID: 34008892
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30Epub 2015 Mar 5. PMID: 25741868; PMCID: PMC4544753
Napolitano F, Dell’Aquila M, Terracciano C, Franzese G, Gentile MT, Piluso G, Santoro C, Colavito D, Patanè A, De Blasiis P, Sampaolo S, Paladino S, Melone MAB (2022) Genotype-phenotype correlations in neurofibromatosis type 1: identification of Novel and recurrent NF1 gene variants and correlations with neurocognitive phenotype. Genes (Basel) 13(7):1130. https://doi.org/10.3390/genes13071130. PMID: 35885913; PMCID: PMC9316015
Cao H, Alrejaye N, Klein OD, Goodwin AF, Oberoi S (2017) A review of craniofacial and dental findings of the RASopathies. Orthod Craniofac Res 20(1):32–38. https://doi.org/10.1111/ocr.12144. PMID: 28643916; PMCID: PMC5942188
Luna M, Wolsefer N, Zambrano CX, Stojanov IJ (2022) Giant cell lesions of the Jaws Involving RASopathy syndromes. Acta Stomatol Croat 56(1):77–88. https://doi.org/10.15644/asc56/1/9. PMID: 35382488; PMCID: PMC8972480
Martínez-Tello FJ, Manjón-Luengo P, Martin-Pérez M, Montes-Moreno S (2005) Cherubism associated with neurofibromatosis type 1, and multiple osteolytic lesions of both femurs: a previously undescribed association of findings. Skeletal Radiol 34(12):793–798. https://doi.org/10.1007/s00256-005-0938-3. Epub 2005 Aug 11. PMID: 16096755
Miri O, Bonnet N, Lysy P, Loucheur N, Gayito R, Docquier PL (2018) Multifocal pigmented Villonodular synovitis in the Noonan Syndrome. Case Rep Orthop 2018:7698052. https://doi.org/10.1155/2018/7698052. PMID: 30631623; PMCID: PMC6305014
Rauen KA, Cardiofaciocutaneous Syndrome (2007) Jan 18 [updated 2023 Feb 9]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds) GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA). 1993–2023. PMID: 20301365.
Suhanya J, Aggarwal C, Mohideen K, Jayachandran S, Ponniah I (2010) Cherubism combined with epilepsy, mental retardation and gingival fibromatosis (Ramon syndrome): a case report. Head Neck Pathol 4(2):126–131. https://doi.org/10.1007/s12105-009-0155-9Epub 2009 Dec 11. PMID: 20512637; PMCID: PMC2878617
Nosé V, Lazar AJ (2022) Update from the 5th Edition of the World Health Organization Classification of Head and Neck tumors: familial tumor syndromes. Head Neck Pathol 16(1):143–157. https://doi.org/10.1007/s12105-022-01414-zEpub 2022 Mar 21. PMID: 35312981; PMCID: PMC9018953
Lessa MM, Sakae FA, Tsuji RK, Filho BC, Voegels RL, Butugan O (2005) Brown tumor of the facial bones: case report and literature review. Ear Nose Throat J 84(7):432–434. PMID: 16813033
Boyce AM, Florenzano P, de Castro LF, Collins MT, Fibrous Dysplasia/McCune-Albright S (2015) Feb 26 [updated 2019 Jun 27]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. PMID: 25719192
Sahu B, Anand R, Kumar S, Solanki RS, Mehra P, Jain M (2021) A Pattern-based Imaging Approach to Pediatric Jaw Lesions. Indian J Radiol Imaging 31(1):210–223. https://doi.org/10.1055/s-0041-1729767. Epub 2021 May 23. PMID: 34316129; PMCID: PMC8299508
Shaw SE, Chan CH (2023) Jan– Non-Odontogenic Tumors of the Jaws. 2023 Jul 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; PMID: 35015466
Bhattacharya S, Mishra RK (2015 Sep-Dec) Fibrous dysplasia and cherubism. Indian J Plast Surg 48(3):236–248. https://doi.org/10.4103/0970-0358.173101. PMID: 26933277; PMCID: PMC4750256
Acknowledgements
Not applicable.
Funding
Open access funding provided by HEAL-Link Greece.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Sofia Sarantou, Anastasios Serbis, Nikolaos M. Marinakis, Joanne Traeger-Synodinos, Aikaterini Siomou and Argyrios Ntinopoulos. The first draft of the manuscript was written by Sofia Sarantou and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethical approval
All patient data were processed and stored according to the guidelines of the General Data Protection Regulation (GDPR). Written informed consent was provided by the patient’s parents. Ethical approval for the genetic study was obtained from St. Sophia Children’s Hospital Scientific and Ethics Committee (Approval number:3669/12 02–18).
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sarantou, S., Marinakis, N.M., Traeger-Synodinos, J. et al. Genetically confirmed coexistence of neurofibromatosis type 1 and Cherubism in a pediatric patient. Mol Biol Rep 51, 216 (2024). https://doi.org/10.1007/s11033-024-09214-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11033-024-09214-0